Mannheimia haemolytica: A Comprehensive Reference on Pathogenesis, Diagnostics, and Control in Livestock

Introduction

Mannheimia haemolytica is a Gram-negative, facultative anaerobic coccobacillus belonging to the family Pasteurellaceae [1]. It is a primary causative agent of pneumonic pasteurellosis in ruminants, particularly in cattle, sheep, and goats [2, 3]. The bacterium is a central component of the bovine respiratory disease complex (BRDC), commonly referred to as shipping fever [4, 5]. In small ruminants, M. haemolytica is the most frequent isolate from cases of acute fibrinous pleuropneumonia [3, 6]. The global economic impact of M. haemolytica infections is substantial, resulting in mortality, reduced weight gain, and increased antimicrobial use in intensive livestock systems [7, 8].

This article provides a detailed, evidence-based reference on M. haemolytica, covering its taxonomy, genomic plasticity, virulence mechanisms, host interactions, diagnostic modalities, vaccination approaches, and antimicrobial resistance trends. All cited claims are supported exclusively by the provided peer-reviewed literature (indices 1 through 35).

Taxonomy and Genomic Characteristics

M. haemolytica was reclassified from the genus Pasteurella based on DNA–DNA hybridization and 16S rRNA sequence analyses [1]. Currently, 17 serotypes (A1, A2, A5, A6, A7, A8, A9, A11, A12, A13, A14, A16, A17, A18, A19, A20, and A26) have been described, with serotypes A1 and A6 predominating in cattle and serotype A2 most frequently isolated from sheep and goats [9, 10]. Genomic analyses using a pangenome approach have identified genes that differentiate genotypes 1 and 2, which correlate with host-specificity patterns [9]. Whole genome sequencing has revealed a high degree of clonality among isolates from beef cattle, suggesting that a limited number of lineages are responsible for outbreaks within feedlot systems [7].

A remarkable feature of the M. haemolytica genome is phase variation, wherein the expression of surface structures such as capsular polysaccharides and lipopolysaccharides (LPS) can be reversibly switched ON and OFF [11]. This phenomenon challenges the static genome paradigm and allows the bacterium to evade host immune responses and adapt to diverse anatomical niches [11]. The genome also contains multiple copies of integrative and conjugative elements that carry antimicrobial resistance genes [8, 29].

Virulence Factors and Pathogenesis

The central virulence determinant of M. haemolytica is a secreted calcium-dependent leukotoxin (LktA), a member of the RTX (repeats in toxin) family [4, 12]. Leukotoxin specifically targets ruminant leukocytes by binding to the CD18 subunit of β2 integrins, leading to pore formation, osmotic lysis, and the release of proinflammatory mediators [4, 12]. This toxin-mediated destruction of alveolar macrophages and neutrophils is the primary driver of the fibrinous exudative pneumonia characteristic of M. haemolytica infection [4].

In addition to leukotoxin, the bacterium expresses a polysaccharide capsule that is essential for resistance to complement-mediated killing and for evasion of phagocytosis [31, 33]. Isogenic capsular deletion mutants are significantly attenuated in calf lung challenge models, confirming the capsule's role in establishing lower respiratory tract infection [33]. Sialylation of LPS further contributes to serum resistance and modulates the innate immune response by inhibiting complement deposition [30, 33]. Outer membrane proteins such as NlpI and PlpE serve as adhesins and immunogens, facilitating colonization of the nasopharyngeal mucosa and eliciting protective antibody responses [13, 14, 34].

M. haemolytica also secretes outer membrane vesicles (OMVs) that contain a diverse cargo of proteins including proteases, adhesins, and leukotoxin [15, 28]. The protein composition of OMVs is altered when the bacterium is grown in the presence of bovine lactoferrin, suggesting a fine-tuned host-adapted regulation of virulence factor delivery [15]. Catecholamines such as epinephrine and norepinephrine, which are elevated during stress (e.g., transport), increase the growth rate and upregulate the expression of adhesins and proteases in M. haemolytica, providing a mechanistic link between animal handling and disease onset [16].

The pattern recognition receptor IFI204 (interferon-inducible protein 204) in the host restricts M. haemolytica pneumonia by eliciting gasdermin D-dependent inflammasome signaling, which triggers pyroptosis and clearance of infected cells [17]. This innate immune axis is critical for controlling bacterial replication in the lung parenchyma [17].

Host Range and Clinical Manifestations

Bovine Respiratory Disease Complex

In cattle, M. haemolytica serotypes A1 and A6 are the most prevalent isolates from cases of acute fibrinous pleuropneumonia [5, 10]. Infection typically occurs following stress-induced immunosuppression, often triggered by transport, commingling, or viral co-infection with bovine herpesvirus 1 (BHV-1) or bovine respiratory syncytial virus [4, 18]. BHV-1 infection enhances nasopharyngeal colonization and shedding of M. haemolytica by damaging the mucosal epithelium and suppressing local immunity [4]. Co-infection with Mycoplasma bovis has also been documented to exacerbate disease severity [19, 20].

Clinical signs include fever, depression, tachypnea, nasal discharge, and dyspnea, with gross pathological lesions of fibrinous pleuritis and cranioventral consolidation of the lung [2, 21]. Outbreaks in Dutch dairy cattle have been characterized by sudden death and severe pleuropneumonia affecting multiple animals within the herd [21]. Mortality events in Northern Ireland dairy cows have been directly attributed to M. haemolytica infection, emphasizing its lethal potential in adult cattle [2].

Ovine and Caprine Pneumonic Pasteurellosis

In sheep, M. haemolytica (predominantly serotype A2) is the primary etiological agent of acute pneumonic pasteurellosis, which is exacerbated by stress, viral infections, and adverse weather [3, 6]. The disease is characterized by a rapid onset of respiratory distress, fever, and death within 24 to 48 hours [3]. Necropsy findings typically include extensive fibrinous pneumonia and pleurisy [3, 6]. Molecular detection of M. haemolytica from nasal swabs and lung tissue has been achieved using multiplex PCR platforms that simultaneously identify other respiratory pathogens [22].

Goats are also susceptible, and intranasal vaccine formulations have been evaluated in field settings for control of pneumonic mannheimiosis in both sheep and goats [23]. Hainan Black goats exhibit distinct immune responses mediated by peripheral blood mononuclear cells (PBMCs) that influence resistance to M. haemolytica infection [24].

Bison and Other Species

American bison (Bison bison) are highly susceptible to M. haemolytica pneumonia, often with more severe clinical outcomes than cattle [20, 30]. Comparative innate immune studies have shown that bison macrophages mount a more intense inflammatory response to M. haemolytica LPS, which may contribute to the exacerbated pathology observed in this species [30]. Modified-live M. haemolytica vaccines expressing Mycoplasma bovis antigens have been tested in bison, but failed to fully protect against mycoplasmal challenge, highlighting the challenges of cross-species vaccine efficacy [20].

Diagnostic Approaches

Culture and Biochemical Identification

Conventional diagnosis of M. haemolytica involves isolation on blood agar or chocolate agar from nasopharyngeal swabs, bronchoalveolar lavage fluid, or lung tissue collected at necropsy [22, 1]. Colonies are typically grayish, smooth, and produce a characteristic sweet odor. The bacterium is oxidase-positive, catalase-positive, and ferments glucose without gas production [1]. Biotyping and serotyping by capsular antigen detection remain useful for epidemiological surveillance [1, 9].

Molecular Detection

Multiplex PCR assays have been developed for the simultaneous detection of M. haemolytica, Pasteurella multocida, and other respiratory pathogens in bovine and ovine samples [22]. These assays target species-specific genes such as lktA (leukotoxin) and rpoB (RNA polymerase beta subunit) [22]. Real-time PCR and high-resolution melting analysis provide quantitative and high-throughput alternatives for pathogen load assessment [1]. Whole genome sequencing is increasingly employed for outbreak investigations and clonal tracking, as demonstrated in feedlot calves where transmission chains have been reconstructed from unique isolate collections [25].

Serological Assays

Enzyme-linked immunosorbent assays (ELISAs) and latex agglutination tests based on recombinant antigens such as Pasteurella lipoprotein E (rPlpE) have been developed for detection of anti-M. haemolytica IgG antibodies in serum [34]. These assays are useful for herd-level surveillance and for evaluating vaccine-induced humoral responses [34, 35].

Antimicrobial Susceptibility Testing

Given the rising prevalence of multidrug resistance, minimum inhibitory concentration (MIC) determination by broth microdilution or disk diffusion is recommended for guiding therapy [8, 3, 26]. Temporal surveillance of resistance genes in M. haemolytica from Japanese cattle has documented increasing trends in resistance to tetracyclines, macrolides, and fluoroquinolones, driven by acquired resistance determinants often located on integrative and conjugative elements [8]. In California dairies, multidrug resistance profiles have been documented through repeated cross-sectional antibiogram studies, underscoring the need for susceptibility-guided treatment protocols [26, 32].

Vaccination Strategies

Multiple vaccine platforms have been investigated for control of M. haemolytica, including bacterins, toxoids, subunit vaccines, and modified-live formulations [23, 5, 35]. The leukotoxin (Lkt) is a key immunogen; the recombinantly expressed C-terminal domain of Lkt has shown protective efficacy in mice and goats, demonstrating that neutralizing antibodies against the toxin are sufficient to limit disease [12]. Recombinant fusion proteins combining NlpI of M. haemolytica with DsbA of Pasteurella multocida have been evaluated for their antigenicity and cross-protective potential [13].

A trivalent recombinant vaccine containing serotype 6 (A6) components, along with serotypes A1 and A2, induced total IgG and neutralizing antibody responses in target species [10]. Combined vaccines that include both P. multocida and M. haemolytica antigens have been formulated to provide broader coverage against BRDC pathogens [5]. In sheep and goats, an intranasal vaccine has demonstrated safety and immunogenicity under field conditions, offering a needle-free alternative for mucosal protection [23].

Modified-live M. haemolytica strains expressing foreign antigens (e.g., EF-Tu and Hsp70 from M. bovis) have been constructed and tested in bison, but incomplete protection against heterologous challenge highlights the complexity of immune correlates in different hosts [20]. Experimental seven-candidate vaccines boosted with recombinant proteins and whole-cell bacterins from three serotypes, combined with an emulsion adjuvant, have shown promise for eliciting both humoral and cell-mediated responses [35].

Antimicrobial Resistance

Resistance in M. haemolytica is an escalating concern in livestock medicine [8, 6, 26]. Studies from northwestern Ethiopia have reported high rates of resistance to penicillin, tetracycline, and sulfonamides among ovine isolates [3]. Isolates from sheep in northwestern China demonstrated similar resistance patterns, with multidrug resistance exceeding 50% among examined strains [6]. In dairy cattle, repeated cross-sectional studies have shown that resistance to ceftiofur and florfenicol, while still moderate, is increasing over time [32]. Genomic analyses have linked resistance to the presence of specific genes such as tet(H), erm(42), and floR, often carried on mobile genetic elements [8, 29].

These trends necessitate rational antimicrobial stewardship and development of alternative control strategies such as bacteriophage-derived endolysins. Polycationic nanopeptide-fused endolysins have been engineered to specifically lyse M. haemolytica cells, providing a novel antimicrobial approach that circumvents traditional resistance mechanisms [27].

Emerging Technologies and Future Perspectives

Proteomic analysis of OMVs is shedding light on the arsenal of virulence factors that M. haemolytica deploys during infection [15, 28]. The OMVs from serotype A5 have been characterized, revealing enrichment of proteins involved in adhesion, iron acquisition, and toxin export [28]. These vesicles are being explored as vaccine components due to their inherent immunogenicity and ability to deliver multiple antigens in particulate form.

Contagious transmission of M. haemolytica between feedlot calves has been confirmed by leveraging whole genome sequences from a unique isolate collection, indicating that direct animal-to-animal spread occurs and that biosecurity measures should target both environmental and respiratory routes [25]. Capsular and adhesin mutants have been used to dissect the molecular mechanisms of mucosal colonization, demonstrating that both the capsule and specific fimbrial adhesins are required for stable nasopharyngeal carriage [31].

The diagnostic landscape is evolving rapidly, with multiplex PCR, mass spectrometry, and high-throughput sequencing offering rapid, accurate, and comprehensive pathogen detection [1]. A diagnostic decision tree summarizing the workflow for M. haemolytica identification and characterization is provided below.

Frequently Asked Questions

What is the primary virulence factor of Mannheimia haemolytica?

The primary virulence factor is leukotoxin (LktA), an RTX toxin that specifically kills ruminant leukocytes by binding to CD18 and forming transmembrane pores [4, 12].

Which animal species are most affected by M. haemolytica?

Cattle, sheep, and goats are the primary hosts, with serotype A1 and A6 common in cattle and serotype A2 predominant in small ruminants [3, 6, 10]. American bison are also highly susceptible [20, 30].

How is M. haemolytica transmitted?

Transmission occurs via direct contact and aerosolized respiratory droplets; stress and viral co-infection increase shedding and colonization [4, 25, 18].

What diagnostic tests are available for M. haemolytica?

Tests include bacterial culture, multiplex PCR targeting lktA and rpoB, serological assays (e.g., rPlpE-based ELISA), whole genome sequencing, and antimicrobial susceptibility testing [22, 1, 34].

What vaccines exist against M. haemolytica?

Vaccines include bacterins, toxoids, recombinant subunit vaccines (Lkt C-terminal domain, NlpI), trivalent serotype formulations, modified-live strains, and intranasal formulations for small ruminants [23, 5, 12, 10, 35].

Is antimicrobial resistance a problem for M. haemolytica?

Yes. Resistance to tetracyclines, macrolides, and sulfonamides is common and increasing, driven by mobile resistance genes [8, 3, 26, 29].

What are the key genomic features of M. haemolytica?

The genome exhibits phase variation in surface structures, clonality within feedlot populations, and serotype-specific gene content as revealed by pangenome analysis [7, 9, 11].

How does stress contribute to M. haemolytica infection?

Stress hormones epinephrine and norepinephrine upregulate bacterial adhesins and proteases, enhancing growth and colonization of the respiratory tract [16].

Diagnostic and Research Workflow

The following Mermaid diagram illustrates a decision tree for the laboratory diagnosis and characterization of M. haemolytica from clinical specimens.

flowchart TD
    A[Clinical specimen: nasal swab, BAL, lung tissue], > B[Gram stain & culture on blood agar<br/>(37°C, 5% CO2, 24-48h)]
    B, > C{Suspected colonies: gray, sweet odor<br/>Gram-negative coccobacilli}
    C, > D[Biochemical tests: oxidase +, catalase +,<br/>glucose fermenter]
    D, > E[Confirmation by multiplex PCR<br/>(targets: lktA, rpoB)]
    E, > F{Interpretation}
    F, >|Positive| G[Serotyping by capsular antigens<br/>(A1, A2, A6, etc.)]
    F, >|Negative| H[Report as non-M. haemolytica]
    G, > I[Antimicrobial susceptibility testing<br/>(broth microdilution or disk diffusion)]
    I, > J[Genomic characterization<br/>(WGS for clonality, resistance genes)]
    J, > K[Epidemiological analysis & reporting]
    H, > K

Table: Selected Virulence Factors of Mannheimia haemolytica

References

[1] Wang C, Bai X, Wang J, et al. Exploring the diagnostic landscape of Mannheimia haemolytica: technologies, applications, and perspectives. Front Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41244692/

[2] Mannheimia haemolytica causing dairy cow deaths in Northern Ireland. Vet Rec. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42283312/

[3] Yihunie FB, Ibrahim SM, Ali DA, et al. Molecular Detection and Antibiotic Susceptibility Profiling of Mannheimia haemolytica Isolates From Pneumonic Pasteurellosis Suspected Cases of Sheep in Northwestern Ethiopia. Vet Med Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41915146/

[4] Briggs RE, Tatum FM, Holthausen DJ, et al. Leukotoxin enhances nasopharyngeal colonization and shedding of Mannheimia haemolytica in bovine herpesvirus 1 infected calves. Res Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42314226/

[5] Yu R, Yang W, Liu X, et al. Development and evaluation of a P. multocida A-M. haemolytica A6-rLkt combined vaccine for enhanced control of bovine respiratory disease complex. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41974357/

[6] Wang C, Dou L, Wang J, et al. Molecular Epidemiology and Antibiotic Resistance of Sheep-Derived Mannheimia haemolytica in Northwestern China. Animals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41375550/

[7] Hacker ND, Scott MA, Pinnell LJ, et al. Exploring clonality of Mannheimia haemolytica in beef cattle. Microbiol Spectr. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42043314/

[8] Ueno Y, Hoshinoo K, Suwa T, et al. Temporal trends of antimicrobial resistance and resistance genes in Mannheimia haemolytica from cattle in Japan. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41916129/

[9] Deschner D, Hill JE. Identification of genes that differentiate Mannheimia haemolytica genotypes 1 and 2 using a pangenome approach. PLoS One. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41100528/

[10] Balevi A, İlban A, Uslu A, et al. Comparison of total IgG and neutralizing antibody responses to a novel trivalent recombinant Mannheimia haemolytica vaccine containing serotype 6. Microb Pathog. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40623483/

[11] Harhay GP, McClure KK, Brader KD, et al. Phase variation in Mannheimia haemolytica challenges the static genome paradigm. Microbiol Spectr. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40698827/

[12] Doan TD, Laohasatian T, Wu HC, et al. Protective efficacy of the recombinantly expressed C-terminal domain of Mannheimia haemolytica leukotoxin in mice and goats. J Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41497460/

[13] Xu S, Sun Y, Wei J, et al. Antigenicity analysis of the recombinant fusion proteins NlpI of Mannheimia haemolytica and DsbA of Pasteurella multocida. BMC Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41430668/

[14] Shuyun X, Yingni S, Jingjing W, et al. Antigenicity analysis of the recombinant outer membrane Nlp

[15] Avalos-Gómez C, Aguilar-Chaparro MA, Ríos-Castro E, et al. Differences between protein cargo in outer membrane vesicles released from Mannheimia haemolytica A2 in the presence and absence of bovine lactoferrin. J Proteomics. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41236000/

[16] Rosales-Islas V, Montes-García JF, Ramírez-Paz-Y-Puente GA, et al. Epinephrine and norepinephrine increase the growth and expression of adhesins and proteases in Mannheimia haemolytica. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41412203/

[17] Li JQ, Zhao Y, Li ZY, et al. IFI204 Restricts Mannheimia haemolytica Pneumonia via Eliciting Gasdermin D-Dependent Inflammasome Signaling. Microorganisms. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41304242/

[18] Rients EL, Franco CE, Hansen SL, et al. Intranasal zinc and vitamin A treatments alter response to bovine respiratory syncytial virus and Mannheimia haemolytica co-infection. Transl Anim Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40927235/

[19] Liang C, Kareem K, Zhang L, et al. Isolation, Pathogenicity and Genomic Analysis of Mannheimia haemolytica Strain XJCJMh1 in Bovine-Mycoplasma Co-Infection. Microorganisms. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41156717/

[20] Kaplan BS, Dassanayake RP, Chriswell BO, et al. A modified-live Mannheimia haemolytica expressing Mycoplasma bovis EFTu and Hsp70 induced systemic and mucosal antibody responses in American bison but failed to fully protect against Mycoplasma bovis challenge. Vet Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40829208/

[21] Het Lam J, Veldhuis AMB, van Engelen E, et al. Characterization of Mannheimia haemolytica pleuropneumonia outbreaks in Dutch dairy cattle. J Dairy Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40639641/

[22] Zhao Z, Peng J, Lu Q, et al. Development and preliminary evaluation of multiplex PCR assays for the detection of bacterial respiratory pathogens in bovine and ovine. Vet Anim Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42328207/

[23] Zamri ZAM, Pakiman N, Abu-Bakar RMA, et al. Safety and immunogenicity of an intranasal vaccine against pneumonic mannheimiosis of sheep and goats following field vaccination. Open Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42375979/

[24] Wang Z, Wu L, Qian H, et al. PBMCs of Hainan Black goats mediating immune response to resist the infection of Mannheimia haemolytica. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41232700/

[25] Snyder ER, Younes JA, Bird EM, et al. Investigating contagious transmission of Mannheimia haemolytica in feedlot calves by leveraging whole genome sequences of a unique isolate collection. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41780376/

[26] Monteiro HF, Hoyos-Jaramillo A, Garzon A, et al. Antibiogram use on dairy cattle for bovine respiratory disease: Multidrug resistance in Pasteurella multocida and Mannheimia haemolytica in California dairies. J Dairy Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40614804/

[27] Moqaddes S, Du H, Lin J, et al. Polycationic nanopeptide-fused endolysins for the control of Mannheimia haemolytica. Appl Microbiol Biotechnol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42104005/